Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | TMEM97 | Q5BJF2 | 6/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | BCL2 | P10415 | 1/20 | 0.40 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.40 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
| ▸ | THRA | P10827 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | KDM5A | P29375 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3547492 | 0.89 | MEN1 (0.54) | KMT2AMEN1TSHRHTTSMN1; SMN2 | |
| SCHEMBL3545420 | 0.86 | MEN1 (0.50) | KMT2AMEN1TSHRHTTSMN1; SMN2 | |
| SCHEMBL3542265 | 0.83 | TMEM97 (0.53) | KMT2ATMEM97SIGMAR1ALDH1A1 | |
| SCHEMBL3545762 | 0.81 | THRA (0.41) | KMT2AMEN1TMEM97SIGMAR1ALDH1A1 | |
| SCHEMBL3547639 | 0.81 | BCL2 (0.45) | KMT2AMEN1TSHRHTTSMN1; SMN2 | |
| SCHEMBL3541063 | 0.80 | MEN1 (0.43) | KMT2AMEN1TSHRHTTSMN1; SMN2 | |
| SCHEMBL8353650 | 0.80 | TMEM97 (0.45) | HTTSMN1; SMN2TMEM97SIGMAR1ALDH1A1 | |
| SCHEMBL3545422 | 0.77 | CA2 (0.41) | KMT2AMEN1TSHRHTTSMN1; SMN2 | |
| SCHEMBL3611347 | 0.77 | TSHR (0.43) | KMT2AMEN1TSHRHTTSMN1; SMN2 | |
| SCHEMBL12951454 | 0.77 | HDAC1 (0.44) | KMT2AMEN1TSHRHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7683078-B2 | Arylsulfonamide derivatives as C-Jun-N-Terminal Kinases (JNK's) inhibitors | LABORATOIRES SERONO S.A. (CH) | 2010-03-23 | — | — | US | claimed |
| EP-1409483-B1 | ARYLSULFONAMIDE DERIVATIVES AS C-JUN-N-TERMINAL KINASES (JNK'S) INHIBITORS | SERONO LAB (CH) | 2008-12-31 | — | — | EP | claimed |
| US-20040248886-A1 | Pharmaceutically active sulfonamide derivatives as c-jun-n-terminal kinases (jnk's) inhibitors | MERCK SERONO SA (CH) | 2004-12-09 | — | — | US | claimed |
| EP-1409483-A1 | ARYLSULFONAMIDE DERIVATIVES AS C-JUN-N-TERMINAL KINASES (JNK'S) INHIBITORS | Applied Research Systems ARS Holding N.V. (AN) | 2004-04-21 | — | — | EP | claimed |
| WO-2003010164-A1 | ARYLSULFONAMIDE DERIVATIVES AS C-JUN-N-TERMINAL KINASES (JNK'S) INHIBITORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2003-02-06 | — | — | WO | claimed |
| US-20150313881-A1 | Therapeutic Methods for Type I Diabetes | UNIVERSITY OF MASSACHUSETTS | 2015-11-05 | — | — | US | disclosed |
| US-8501812-B2 | Therapeutic methods for type I diabetes | UNIVERSITY OF MASSACHUSETTS (US) | 2013-08-06 | — | — | US | disclosed |
| US-20120208846-A1 | Therapeutic Methods For Type I Diabetes | UNIVERSITY OF MASSACHUSETTS | 2012-08-16 | — | — | US | disclosed |
| US-7897572-B1 | Theraputic methods for type I diabetes | UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL (US) | 2011-03-01 | — | — | US | disclosed |
| US-7683078-B2 | Arylsulfonamide derivatives as C-Jun-N-Terminal Kinases (JNK's) inhibitors | LABORATOIRES SERONO S.A. (CH) | 2010-03-23 | — | — | US | disclosed |
| US-7683078-B2 | Arylsulfonamide derivatives as C-Jun-N-Terminal Kinases (JNK's) inhibitors | LABORATOIRES SERONO S.A. (CH) | 2010-03-23 | — | — | US | disclosed |
| US-7683078-B2 | Arylsulfonamide derivatives as C-Jun-N-Terminal Kinases (JNK's) inhibitors | LABORATOIRES SERONO S.A. (CH) | 2010-03-23 | — | — | US | disclosed |
| US-20100029719-A1 | ARYLSULFONAMIDE DERIVATIVES AS C-JUN-N-TERMINAL KINASES (JNK'S) INHIBITORS | LABORATOIRES SERONO S.A. (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20100029719-A1 | ARYLSULFONAMIDE DERIVATIVES AS C-JUN-N-TERMINAL KINASES (JNK'S) INHIBITORS | LABORATOIRES SERONO S.A. (CH) | 2010-02-04 | — | — | US | disclosed |
| EP-1409483-B1 | ARYLSULFONAMIDE DERIVATIVES AS C-JUN-N-TERMINAL KINASES (JNK'S) INHIBITORS | SERONO LAB (CH) | 2008-12-31 | — | — | EP | disclosed |
| EP-1409483-B1 | ARYLSULFONAMIDE DERIVATIVES AS C-JUN-N-TERMINAL KINASES (JNK'S) INHIBITORS | SERONO LAB (CH) | 2008-12-31 | — | — | EP | disclosed |
| WO-2006104983-A1 | THERAPEUTIC METHODS FOR TYPE I DIABETES | UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL (US) | 2006-10-05 | — | — | WO | disclosed |
| US-20040248886-A1 | Pharmaceutically active sulfonamide derivatives as c-jun-n-terminal kinases (jnk's) inhibitors | MERCK SERONO SA (CH) | 2004-12-09 | — | — | US | disclosed |
| EP-1409483-A1 | ARYLSULFONAMIDE DERIVATIVES AS C-JUN-N-TERMINAL KINASES (JNK'S) INHIBITORS | Applied Research Systems ARS Holding N.V. (AN) | 2004-04-21 | — | — | EP | disclosed |
| WO-2003010164-A1 | ARYLSULFONAMIDE DERIVATIVES AS C-JUN-N-TERMINAL KINASES (JNK'S) INHIBITORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248886-A1 | Pharmaceutically active sulfonamide derivatives as c-jun-n-terminal kinases (jnk's) inhibitors | MAPK1, MAPK3, MAP3K2 | KMT2A 1675/4885MEN1 3849/4885TSHR 1232/4885 |
| US-20150313881-A1 | Therapeutic Methods for Type I Diabetes | MAPK9, IAPP, RNASE1 | KMT2A 2064/4885MEN1 3910/4885TSHR 1205/4885 |
| US-20120208846-A1 | Therapeutic Methods For Type I Diabetes | MAPK9, IAPP, RNASE1 | KMT2A 2064/4885MEN1 3910/4885TSHR 1205/4885 |
| US-20100029719-A1 | ARYLSULFONAMIDE DERIVATIVES AS C-JUN-N-TERMINAL KINASES (JNK'S) INHIBITORS | MAPK1, MAPK3, MAP3K2 | KMT2A 1673/4885MEN1 3062/4885TSHR 2014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.